Dasacine, a Chemo Drug that targets Blood Cancer

Arechar Healthcare, one of the foremost life-saving drug manufacturers, is all set for the launch of Dasatinib, under the brand name Dasacine, which is expected to be the best solution for the easy treatment of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). It has been evident that the risk of developing cancer is increasing with the ignorance of healthcare among the people. Even after the diagnosis, the patients aren’t able to get the right and timely treatment. To increase accessibility, Arechar Healthcare has come up with such life-saving drugs and has prioritized the most serious sector of treatment.

“With the launch of Dasacine, I feel happy to manifest my contribution to the healthcare sector, specifically oncology, for I know the value of the human lives being disturbed by cancer and tumors,” said Harpreet Singh, Founder of Arechar Healthcare. “Dasacine is an orally bioavailable synthetic small molecule-inhibitor, which is a multi-targeted kinase inhibitor that can act as an essential element in the treatment of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL), with the highest efficacy.”

“With the increasing incidence of cancer in our world, we strive to bestow the best life-saving drugs, keeping in mind the accessibility and affordability of the medicines we offer. Humanity comes from actions based on our beliefs, therefore we execute the humanitarian beliefs with such steps towards healthcare, specifically in the field of oncology,” he added.

Dasatinib is a targeted therapy. It is used in the treatment of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). The molecular weight of Dasatinib is 488 g/mol. It is a tyrosine-kinase inhibitor. Its molecular formula is C22H26ClN7O2S.

Dasacine is a  prescription medicine used in the treatment of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). It is available in the strength of 50 mg and 70 mg.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top